

1 Hemoglobin modifies the effect of hypoxemia on  
2 COVID-19 mortality

3  
4 The interaction effect between hemoglobin and  
5 hypoxemia on COVID-19 mortality in a sample from  
6 Bogotá, Colombia: An exploratory study.

7  
8 Andrés Felipe Patiño-Aldana<sup>1</sup>, Angela María Ruíz-Sternberg<sup>1</sup>, Angela María Pinzón-Rondón<sup>1\*</sup>,  
9 Nicolás Molano-González<sup>1</sup>, David Rene Rodríguez Lima<sup>2</sup>

10  
11  
12  
13  
14 <sup>1</sup>Clinical Research Group, Universidad del Rosario, Bogotá, Colombia

15 <sup>2</sup>CIMED, Hospital Universitario Mayor - Méderi, Bogotá, Colombia

16  
17  
18  
19  
20  
21 \*Corresponding author:

22 E-mail: [angela.pinzon@urosario.edu.co](mailto:angela.pinzon@urosario.edu.co)

23  
24  
25

## 26 **Abstract:**

27 **Purpose:** We aimed to assess the effect of hemoglobin (Hb) concentration and oxygenation  
28 index on COVID-19 patients' mortality risk.

29 **Patients and methods:** We retrospectively reviewed sociodemographic and clinical  
30 characteristics, laboratory findings, and clinical outcomes from patients admitted to a tertiary care  
31 hospital in Bogotá, Colombia. We assessed exploratory associations between oxygenation index  
32 and Hb concentration at admission and clinical outcomes. We used a generalized additive model  
33 (GAM) to evaluate the nonlinear relations observed and the classification and regression trees  
34 (CART) algorithm to assess the interaction effects found.

35 **Results:** From March to July 2020, 643 patients were admitted, of which 52% were male. The  
36 median age was 60 years old, and the most frequent comorbidity was hypertension (35.76%).  
37 The median value of  $SpO_2/FiO_2$  was 419, and the median Hb concentration was 14.8 g/dL. The  
38 mortality was 19.1% (123 patients). Age, sex, and history of hypertension were independently  
39 associated with mortality. We described a nonlinear relationship between  $SpO_2/FiO_2$ , Hb  
40 concentration and neutrophil-to-lymphocyte ratio with mortality and an interaction effect between  
41  $SpO_2/FiO_2$  and Hb concentration. Patients with a similar oxygenation index had different mortality  
42 likelihoods based upon their Hb at admission. CART showed that patients with  $SpO_2/FiO_2 < 324$ ,  
43 who were older than 62 years, and had an Hb of  $\geq 16$  g/dl had the highest mortality risk (96%).  
44 Additionally, patients with  $SpO_2/FiO_2 > 324$  but Hb of  $< 12$  and neutrophil-to-lymphocyte ratio of  $>$   
45  $4$  had a higher mortality likelihood (57%). In contrast, patients with  $SpO_2/FiO_2 > 324$  and Hb of  $>$   
46  $12$  g/dl had the lowest mortality risk (10%).

47 **Conclusion:** We found that a decreased  $SpO_2/FiO_2$  increased mortality risk. Extreme values of  
48 Hb, either low or high, showed an increase in likelihood of mortality. However, Hb concentration  
49 modified the  $SpO_2/FiO_2$  effect on mortality; the likelihood of death in patients with low  $SpO_2/FiO_2$   
50 increased as Hb increased.

51

52 **Keywords:** Hypoxia; Erythrocytosis; Acute respiratory infection; SARS-CoV-2; Neutrophil-to-  
53 lymphocyte ratio; Generalized additive model; Classification and regression tree.

54

## 55 **Introduction**

56 On December 31, 2019, SARS-CoV-2 emerged in China and rapidly spread worldwide, with more  
57 than 293 million infections and 5.4 million deaths.[1] In Colombia, which is a developing country,  
58 as of January 5th, there have been more than 5.2 million cases, with more than 130,000 deaths  
59 in the national territory. In Bogota, the most affected city in the country, there have been more  
60 than 1.49 million people infected and 27,846 people have died.[2,3]

61

62 Several studies worldwide have associated factors with mortality in COVID-19 patients. Most  
63 studies have been consistent with risk factors for severe disease. Studies in Asia reported age,  
64 history of smoking, vital signs at admission, albumin, C-reactive protein, and proinflammatory  
65 cytokines as risk factors for disease progression.[4,5] Studies in the USA described factors such  
66 as oxygenation ( $SpO_2/FiO_2$ ) at admission, age, heart failure, sex, nursing home residency,  
67 respiratory rate, and body mass index (BMI) as the main predictors associated with COVID-19  
68 critical illness.[6,7] These factors might be linked to a hyperinflammatory syndrome, which favors  
69 an exaggerated immune response and organ failure when facing a viral infection.[8,9]

70

71 Some ecological studies have evaluated COVID-19 mortality in high-altitude places, but the  
72 results are contradictory. Some authors reported higher mortality in men younger than 65 years  
73 old living in the USA and Mexico at >2,000 m elevation than in those located <1,500 m.[10] Other  
74 studies developed in an Andean population (Colombia and Perú) showed a negative correlation  
75 between high altitude and COVID-19 mortality and lower mortality excess.[11–13] People who  
76 permanently live in high-altitude places develop adaptative mechanisms against low atmospheric  
77 oxygen pressure exposure. In locations such as Bogotá, which has an altitude of more than 2,500  
78 meters, there is a decrease in mean  $SpO_2$  values among its population.[14] People who live in

79 high altitude locations develop ventilatory, cardiovascular, reproductive, and even cognitive  
80 changes. [15,16]

81

82 As part of the compensatory mechanisms, erythrocyte concentration in the blood increases.  
83 Initially, it is caused by a fast reduction in plasma volume. Additionally, hypoxia leads to an  
84 erythropoietic stimulus through hypoxia-inducible factor 1-alpha (HIF1- $\alpha$ ) activation that binds  
85 hypoxia-inducible factor 1-beta (HIF1- $\beta$ ). Together, they act as a promoting factor for  
86 erythropoietin (EPO) stimulating red blood cell (RBC) production.[17] High altitude also leads to  
87 hyperventilation driven by an increased tidal volume and respiratory rate. Living in a high-altitude  
88 place is related to alveolar and arterial hypoxemia. A person at sea level will have an alveolar  
89 oxygen pressure between 90 and 100 mm Hg, a resident at Bogotá will reach a PaO<sub>2</sub> between  
90 60 and 70 mmHg, while someone at 5,100 m elevation will have a PaO<sub>2</sub> of 43 mmHg.[18–20]  
91 The adaptative mechanisms allow for the survival of populations conditioned to these harsh  
92 environments. However, studies of people living at high altitudes have described increases in the  
93 O<sub>2</sub> maximum consumption as they descend to sea level, highlighting the physiologically  
94 challenging condition imposed by low oxygen pressures for oxygen uptake and utilization.[18]

95

96 Numerous studies have proposed hemoglobin (Hb) as a biomarker of severe COVID-19.[21]  
97 Anemia is a marker of chronic disease and a risk factor in critical ill patients. Limited oxygen-  
98 carrying capacity and delivery might play a crucial role in organ failure development. Thus,  
99 increasing the likelihood of severity and mortality.[21,22] A recent meta-analysis found a lower  
100 mean Hb concentration between moderate and severe cases, but did not find significant  
101 differences between survivors and nonsurvivors.[21]

102

103 Adaptative mechanisms to high altitude are related to oxygen intake, transport, and the  
104 availability for tissues. Patients with acute respiratory infections who live in high altitude face a  
105 convergence between pathological and adaptive processes. Mechanisms that could be

106 interrelated moderating the disease outcome. Our research aimed to assess the effect of Hb and  
107 oxygenation index on COVID-19 mortality.

## 108 **Materials and methods**

### 109 **Study population**

110 We performed an observational, retrospective study between March and July 2020. We followed  
111 a cohort of COVID-19 patients admitted to the Hospital Universitario Mayor Méderi (HUM) in  
112 Bogotá, Colombia. In this study, we used a cutoff date of July 2020. We included patients with  
113 confirmed infection of SARS-CoV-2 by RT-PCR or antigen. We excluded patients with a history  
114 of anemic, lymphoproliferative, or myelodysplastic syndromes. We also excluded patients with  
115 information of permanent residency under 2,500 meters above sea level (MASL) and without  
116 complete blood count (CBC) measurement. The Ethics Committee of the Universidad del Rosario  
117 approved the research protocol. Qualified professionals carried out all activities and procedures  
118 following the principles outlined in the Declaration of Helsinki.

### 119 **Variables and main outcomes**

120 Data were collected from clinical records through a comprehensive review of hospital admission  
121 information. A CBC was taken only in patients with hospital admission criteria that required  
122 laboratory assessments, and who received at least a few hours of in-hospital observation. The  
123 CBC was processed in HUM's clinical laboratory using a Sysmex XN-1000 hematology analyzer.  
124 In cases of low-flow systems that could not deliver constant  $FiO_2$ , we took clinically recorded  
125  $FiO_2$ . A nasal cannula increased  $FiO_2$  by approximately 0.4% per liter/min. A nonrebreather mask  
126 with a flow output higher than 10 L/min was taken as 100%  $FiO_2$ . [23] We calculated variables  
127 such as  $SpO_2/FiO_2$ , mean arterial pressure (MAP), and neutrophil to lymphocyte ratio (NLR). We  
128 defined the discharge condition (alive or dead) as the primary outcome.

129

### 130 **Statistical analysis**

131 We reported qualitative variables as frequencies and percentages, and quantitative variables as  
132 the means and standard deviations or medians and interquartile ranges, depending on the  
133 normality of the distribution (tested by Shapiro–Wilk test). To assess the possible associations  
134 with mortality, we performed an exploratory analysis using the Mann–Whitney test or the chi-  
135 square of independence test for quantitative and qualitative variables, respectively. We made a  
136 purposeful selection of covariates for the multivariate model, as described by Hosmer,  
137 Lemeshow, and Sturdivant.[24] Appraising to nonlinear relations found, we built a generalized  
138 additive model (GAM), estimating linear and nonlinear effects. Instead of a single regression  
139 coefficient, GAM estimates a k number of base functions, which in sum describes the functional  
140 form of the relationship between dependent and independent variables.[25] We tested for  
141 interaction effects using tensor products in the GAM model. Notably, the tensor smoothing  
142 function (TI) calculates different k base functions for each variable included in the interaction  
143 effect, and it is useful for variables with different scales. [24,25]

144

145 In a second approach, we used the classification and regression tree (CART) algorithm to find the  
146 most relevant variables associated with the clinical outcome.[26] We set the overall significance  
147 level at 5%. The sampling method was not probabilistic and consecutive. We defined the sample  
148 size by convenience. Thus, the analyses were exploratory. We used R version 4.0.2 software for  
149 statistical analyses.

150

## 151 **Results**

152 From March to July 2020, 1,000 patients were diagnosed with SARS-CoV-2 infection at HUM,  
153 and 650 met the inclusion criteria with in-hospital admittance and CBC measurement. We  
154 excluded seven patients because they met the exclusion criteria. Four of them had a history of  
155 anemia, two hematologic malignancies, and one permanent residency at low altitude (< 2,500  
156 MASL), yielding 643 patients included in this study.

157

158 The median (interquartile range) age was 60 years old (46-73), and 52.56% of patients were  
 159 male. The more frequent comorbidities were hypertension (35.76%), diabetes (18.04%), COPD  
 160 (9.92%), and chronic kidney disease (CKD) (5.9%). The median MAP and SpO<sub>2</sub>/FiO<sub>2</sub> were 92  
 161 mmHg (83.7-101.9) and 419 (359.5-438), respectively. Regarding the CBC on admission, the  
 162 median white blood cell count (WBC) was 7.11 (5.29-9,71) x 10<sup>3</sup> cells/μL, and the median  
 163 concentration of Hb was 14.8 g/dL (13.5-15.9). Among the total sample, 123 patients (19.12%)  
 164 died and 520 (80.87%) survived.

165

166 Table 1 shows the proportion of characteristics and median differences in vital signs and CBC by  
 167 discharge condition with an exploratory hypothesis test result. We found a statistically significant  
 168 difference in the proportion of males between survivors and nonsurvivors. Additionally, there was  
 169 statistically significant difference in age and the number of patients with a history of hypertension,  
 170 COPD, and CKD. Concerning vital signs, we found statistically significant differences in the  
 171 median respiratory rate, FiO<sub>2</sub>, SpO<sub>2</sub>, and SpO<sub>2</sub>/FiO<sub>2</sub>. Regarding CBC, there were differences  
 172 between survivors and nonsurvivors patients in terms of median WBC, RBC count, absolute  
 173 lymphocyte count (ALC), absolute neutrophil count (ANC), Hb, NLR, and several percent white  
 174 blood cell relations.

175

176 **Table 1** Demographic characteristics, comorbidity history, vital signs, and complete blood count  
 177 by discharge condition in COVID-19 patients.

178

Variable	Alive n = 520(80.8%)	Dead n = 123(19.1%)	Total n (%) N = 643	P value*
Sex				
Female	260 (50%)	45 (37%)	305(47.4%)	0.010
Male	260 (50%)	78 (63%)	338 (52.56%)	
Age Median (IQR)	57 (42-69)	74 (62.5-82)	60 (46-73)	<0.001

Smoke history n (%)				
Current	12 (2%)	2 (1%)	13 (2.04%)	0.232
Former	29 (6%)	11 (9%)	40 (6.29%)	
Never	472 (92%)	109 (90%)	582 (91.65%)	
<b>Comorbidities History n(%)</b>				
Hypertension	156 (30.0%)	74 (60.2%)	230 (35.76%)	<0.001
Dyslipidemia	8 (1.5%)	6 (4.9%)	14 (2.17%)	0.053
Cardiovascular disease	25 (4.8%)	6 (4.9%)	31 (4.82%)	1.000
Heart failure	18 (3.5%)	7 (5.7%)	25 (3.88%)	0.373
Asthma	8 (1.5%)	1 (0.8%)	9 (1.39%)	0.850
COPD	31 (6.0%)	27 (22.0%)	58 (9.02%)	<0.001
Diabetes	86 (16.5%)	30 (24.4%)	117 (18.04%)	0.057
Cerebrovascular disease	9 (1.7%)	5 (4.1%)	14 (2.17%)	0.211
Atrial fibrillation	13 (2.5%)	6 (4.9%)	19 (2.95%)	0.269
Chronic kidney disease	21 (4.0%)	17 (13.8%)	38 (5.90%)	<0.001
Liver disease	4 (0.8%)	1(0.0%)	4 (0.62%)	0.735
Autoimmune disease	10 (1.9%)	5 (4.1%)	15 (2.33%)	0.279
Hypothyroidism	62 (11.9%)	22 (17.9%)	84 (13.06%)	0.106
HIV	7 (1.3%)	1 (0.8%)	8 (1.24%)	0.978
Psychiatric disease	10 (1.9%)	2 (1.6%)	12 (1.86%)	1.000
<b>Vital Signs Median (IQR)</b>				
Systolic blood pressure	127 (115-140)	131 (119-145)	128 (116-141)	0.073
Diastolic blood pressure	75 (66-84)	72 (63-82)	75 (66-83)	0.096
Mean blood pressure	92 (83.6-101.6)	92.1 (82.4-102.6)	92 (83.7-101.9)	0.850
Heart rate	95 (82-106)	97 (80.5-109.5)	95 (82-106.5)	0.516
Respiratory rate	20 (18-20)	20 (18-22.5)	20 (18-20)	0.001
Temperature	36.5 (36.2-37.1)	36.5 (36.1-37.05)	36.5 (36.2-37.1)	0.192
Fraction inspired O <sub>2</sub> (FiO <sub>2</sub> )	21 (21-21)	21 (21-28)	21 (21-21)	<0.001
Peripheral O <sub>2</sub> saturation (SpO <sub>2</sub> )	91 (87-94)	88 (78-91)	90 (86-93)	<0.001
SpO <sub>2</sub> /FiO <sub>2</sub>	424 (386-443)	352 (286.5-426.5)	419 (359.5-438)	<0.001
BMI	26.7 (24-30.1)	25.7 (23.1-29.3)	26.6 (23.6-30.1)	0.179
<b>Complete Blood Count Median (IQR)</b>				
WBC	6.6 (5.23-8.97)	8.62(6.43-11.72)	7.11 (5.29-9.71)	<0.001
RBC count	5.06(4.69-5.48)	4.93(4.17-5.48)	5.04 (4.64-5.48)	0.019



Absolute lymphocyte count	1.23(0.9-1.62)	0.88(0.60-1.33)	1.18 (0.82-1.56)	<0.001
Absolute neutrophil count	4.56 (3.3-7)	6.82 (4.5-9.85)	4.96 (3.45-7.73)	<0.001
Hemoglobin	14.9 (13.7-15.9)	14.1 (12.5-15.8)	14.8 (13.5-15.9)	0.011
Hematocrit	44.5 (41.3-47.5)	43 (38.2-47.8)	44.4 (40.7-47.5)	0.052
Mean corpuscular volume	87.7 (84.9-90.9)	88 (85.2-91.6)	87.8 (85-91)	0.101
Platelets	223.5 (178-272)	209 (160.5-277.5)	221 (177-273)	0.179
Neutrophil percentage	71.9 (60.6-81.3)	83.2 (75.1-88,3)	74.4 (62.4-83.2)	<0.001
Basophil percentage	0.2(0.1-0.4)	0.2(0.1-0.4)	0.2 (0.1-0.4)	0.597
Lymphocyte percentage	18.5 (11.5-27.8)	9.8 (6.85-16)	16.7 (10.2-26.35)	<0.001
Monocyte percentage	7.6 (5.1-10.3)	5.7 (4.05-8.4)	7.3 (4.8-10)	<0.001
Eosinophile percentage	0.1 (0-0.5)	0 (0-0.3)	0.1 (0-0.5)	0.002
Neutrophil to lymphocyte ratio	3.91(2.2-7.1)	8(4.6-12.9)	4.4(2.3-8.1)	<0.001

179 \*Exploratory hypothesis testing for purposeful selection of covariates

180 IQR: Interquartile range, COPD: Chronic obstructive pulmonary disease, HIV: Human  
 181 immunodeficiency virus infection, FiO2: Fraction inspired O2, SpO2: Peripheral O2 saturation,  
 182 BMI: Body mass index, WBC: White blood cell count, RBC: Red blood cell.

183

184 We carried out a purposeful selection of covariates for modeling based on statistically significant  
 185 differences found.[24] We found that age, sex, history of hypertension, SpO2/FiO2, Hb, and NLR  
 186 were independently associated with in-hospital mortality. The relationship between age and  
 187 mortality was linear. However, the association between SpO2/FiO2, Hb, and NLR and mortality  
 188 was nonlinear. Thus, as stated earlier, we performed a GAM that included linear and smoothed  
 189 terms. Moreover, we found a significant interaction term between SpO2/FiO2 and hemoglobin.  
 190 Table 2 shows the effects of the linear terms in the independent and interaction GAM. These  
 191 estimations were the same for both models. Table 3 shows the smoothed variables in both  
 192 models and the significance of its smoothed function.

193

194

195 **Table 2 Linear terms of independent effects and interaction generalized additive model**

Linear terms	Coefficient	P value	OR	CI 95%
Intercept	-2.661	<0.001		
Age	0.044	<0.001	1.05	1.03-1.06
Sex: Male	0.783	0.003	2.19	1.28–3.73
Hypertension: Yes	0.611	0.017	1.84	1.11–3.05

196 The estimated effects for linear terms, age, sex, and hypertension history were the same among  
 197 the independent effects model and interaction model.

198

199 **Table 3 Smoothed terms of independent effects and interaction generalized additive model**

Independent effects model		Interaction model	
Smoothed terms	P Value <sup>a</sup>	Smoothed terms	P Value
S <sup>b</sup> (Neutrophil-to-lymphocyte ratio)	<0.001	S(Neutrophil-to-lymphocyte ratio)	<0.001
S (SpO <sub>2</sub> /FiO <sub>2</sub> )	<0.001	TI <sup>c</sup> (SpO <sub>2</sub> /FiO <sub>2</sub> , Hemoglobin)	0.011
S (Hemoglobin)	<0.001		
R <sup>2</sup> = 0.3, AIC = 470		R <sup>2</sup> = 0.252, AIC= 495	

200 <sup>a</sup>P value shown with smoothed and tensor terms tested the H<sub>0</sub>: f(x) = 0. <sup>b</sup>S(): Smoothed term;

201 <sup>c</sup>TI(): Tensor interaction term.

202

203 It is noteworthy that the model with the interaction term had a higher Akaike information criterion  
 204 (AIC) and a lower determination coefficient (R<sup>2</sup>) than the principal effects model, which came at  
 205 the cost of higher complexity. Smoothed variables and interaction effects from the GAM model  
 206 can be better understood visually. Figure 1 presents the functional form of the smoothed  
 207 variable's influence on mortality. Death probability had a positive correlation with NLR. Values of  
 208 SpO<sub>2</sub>/FiO<sub>2</sub> present a sharp increase in the mortality risk under 350-320. Hemoglobin at admission  
 209 had a U-shaped correlation with mortality. Patients with low or high hemoglobin concentrations  
 210 were more prone to die during hospitalization. However, the significant interaction term showed  
 211 us that the Hb and SpO<sub>2</sub>/FiO<sub>2</sub> effects on mortality were modified by each other.

212

213 **Fig. 1. Partial effects of smoothed terms on mortality in GAM**

214 **Figure 1** shows the functional form of the partial effects on mortality of the smoothed terms in  
215 GAM. 1A) Positive correlation between NLR and mortality risk. 1B) Decreases in  $\text{SpO}_2/\text{FiO}_2$   
216 values lead to a sharp increase in death risk. 1C) U-shaped relationship between Hb  
217 concentration and mortality risk, patients with Hb either high or low values had an increased  
218 mortality risk. Inside parentheses are the smoothed term and its effective degrees of freedom  
219 (EDF), a summary statistic that reflects the degree of nonlinearity. NLR: Neutrophil to lymphocyte  
220 ratio, GAM: Generalized additive model.

221

222 The contour plot in Figure 2 shows how Hb modifies the  $\text{SpO}_2/\text{FiO}_2$  effect on mortality. Notice how  
223 patients with similar  $\text{SpO}_2/\text{FiO}_2$  at admittance had a different likelihood of death according to their  
224 Hb value at admission. For instance, death probability remained constant (10%) across all ranges  
225 of  $\text{SpO}_2/\text{FiO}_2$  values for patients with an Hb between 12-15 g/dL. The likelihood of death was also  
226 10% for those with a high Hb but  $\text{SpO}_2/\text{FiO}_2 > 400$ . However, patients with  $\text{SpO}_2/\text{FiO}_2 < 300$  and  
227 Hb  $> 15$  g/dL had a 20% likelihood of death. This probability increased proportionally as the Hb  
228 concentration rose. It increased to 80% of death likelihood for patients with  $\text{SpO}_2/\text{FiO}_2$  of 300 and  
229 Hb  $> 20$  g/dL and 90% for patients with  $\text{SpO}_2/\text{FiO}_2 < 150$  and an Hb of approximately 18 g/dL.  
230 Additionally, in patients with  $\text{SpO}_2/\text{FiO}_2$  of 400 and Hb  $< 10$  g/dL, the death probability increased  
231 proportionally as Hb decreased, increasing up to 70 to 90% for patients with an Hb of  
232 approximately 5 g/dL. We further explored this interaction effect with a second approach, which is  
233 explained below.

234

### 235 **Fig. 2. Interaction effect between $\text{SpO}_2/\text{FiO}_2$ and Hb on mortality**

236 **Figure 2** shows a contour plot with estimated probabilities of death for given  $\text{SpO}_2/\text{FiO}_2$  values at  
237 different hemoglobin concentrations. Curves show areas where the risk of death is similar. Higher  
238 likelihoods are shown in red, while green indicates lower likelihoods. Patients with similar  
239  $\text{SpO}_2/\text{FiO}_2$  values had different probabilities of death according to hemoglobin concentration.  
240 Notice how decreases in  $\text{SpO}_2/\text{FiO}_2$  get worse as hemoglobin concentration rise. Blanks in the  
241 plot represent data that were not observed.

242

243 Figure 3 shows a CART model, a method that classifies patients according to their likelihood of  
244 death using  $SpO_2/FiO_2$ , Hb, age, and NLR as independent variables. The patients with the  
245 highest probability of death (90%) were those who had  $SpO_2/FiO_2 < 324$ , were older than 62  
246 years, and had an Hb  $> 16$  g/dL. Additionally, patients with an Hb  $< 12$  g/dl and NLR  $> 4$  had a  
247 higher probability of death (57%). In comparison, patients with the lowest likelihood of death  
248 (10%) were those who did have an  $SpO_2/FiO_2 > 324$  and an Hb  $> 12$  g/dL at admission.  
249 Interestingly, the CART method also showed that the hemoglobin concentration at admittance  
250 modified the  $SpO_2/FiO_2$  effect on probability of death.

251

252 **Fig. 3. Classification and regression tree of the mortality of COVID-19 patients.**

253 **Figure 3** Distribution of death and survival across COVID-19 patients. The CART showed seven  
254 differential clinical profiles using  $SpO_2/FiO_2$ , age, Hb concentration, and NLR as predictor  
255 variables. Clinical profiles with a lower probability of death are shown in green, while red indicates  
256 the clinical profiles with a higher likelihood of death. Notice how hemoglobin concentrations both  
257  $< 12$  g/dL and  $\geq 16$  g/dL are features of the clinical profiles with higher mortality likelihood based  
258 upon  $SpO_2/FiO_2$  admission value. Hb: Hemoglobin (g/dl), NLR: Neutrophil to lymphocyte ratio.

259

## 260 Discussion

261 This original research described the nonlinear relations and, to our knowledge, an unrecognized  
262 interaction effect between  $SpO_2/FiO_2$  and Hb on the mortality of patients with SARS-CoV-2 acute  
263 respiratory infection. Using novel multivariate statistical methods to assess nonlinear relations, we  
264 found that  $SpO_2/FiO_2$ , Hb, NLR, age, history of hypertension, and male sex were independently  
265 associated with the probability of death. The  $SpO_2/FiO_2$ , Hb, and NLR values had a nonlinear  
266 relationship with the outcome in GAM. Interestingly, low or high Hb concentrations showed a  
267 sharp quadratic increase in the likelihood of death (Fig. 1). We found a significant interaction

268 between SpO<sub>2</sub>/FiO<sub>2</sub> and Hb effects on mortality (Fig. 2). We explored this further using CART,  
269 which showed that older patients with a lower SpO<sub>2</sub>/FiO<sub>2</sub> and a Hb ≥16 g/dL had the highest  
270 probability of death (90%). Additionally, normoxic (SpO<sub>2</sub>/FiO<sub>2</sub> >324) but anemic patients (<12 g/dl)  
271 with an NLR >4 had a higher probability of death (57%). Normoxic nonanemic patients (>12 g/dl)  
272 had, as expected, the lowest likelihood of death (10%).

273

274 The proportion of death among hospitalized patients was 19.12%, and the cumulative death  
275 incidence between March and July was 95.6 per 500 patients admitted to HUM. The Centers for  
276 Disease Control and Prevention (CDC) reported in-hospital mortality ranging from 8.6% to 23.4%  
277 in approximately the same period.[27] Regarding the oxygenation index, we found a significant  
278 difference in the median SpO<sub>2</sub>/FiO<sub>2</sub> between survivors and nonsurvivors. Some authors have  
279 proposed the SpO<sub>2</sub>/FiO<sub>2</sub> ratio as a continuous noninvasive monitoring tool for assessing  
280 oxygenation in acute respiratory failure, or its use as a surrogate for estimating PaO<sub>2</sub>/FiO<sub>2</sub> in  
281 sepsis.[28,29] The SpO<sub>2</sub>/FiO<sub>2</sub> ratio showed good performance with an AUC =0.801 (95% CI  
282 0.746–0.855) for early mechanical ventilation requirements in patients with COVID-19, even with  
283 better performance than the ROX index. Its sequential assessment showed a sharp decline in  
284 nonsurvivors compared to an increasing shift in survivors.[30] Catoire et al. described an  
285 excellent performance AUC of 0.91 (95% CI 0.885–0.950) of SpO<sub>2</sub>/FiO<sub>2</sub> to estimate PaO<sub>2</sub>/FiO<sub>2</sub>  
286 values in patients with COVID-19 patients.

287

288 We found a significant association between SpO<sub>2</sub>/FiO<sub>2</sub> and mortality. The GAM showed a sharp  
289 increase in the probability of mortality as SpO<sub>2</sub>/FiO<sub>2</sub> decreased (Fig. 1), with a slight decrease at  
290 values under 100. The CART model established a cut point of 324 to define higher-risk groups.  
291 Type I respiratory failure in acute respiratory distress syndrome (ARDS) is stratified by PaO<sub>2</sub>/FiO<sub>2</sub>  
292 evaluation, although some authors have proposed a modified definition for scarce resource  
293 settings using SpO<sub>2</sub>/FiO<sub>2</sub> assessment.[31] Berlin's definition has allowed stratifying patients  
294 based on oxygenation compromise. There is a correlation between disease severity measured by

295 PaO<sub>2</sub>/FiO<sub>2</sub> and mortality risk. However, it has a limited prognostic performance with an AUC of  
296 0.57 (95% CI 0.561-0.593).

297

298 For instance, patients with severe ARDS (PaO<sub>2</sub>/FiO<sub>2</sub> values <100) have a differential prognosis  
299 according to distensibility and expiratory volume. Higher expiratory volume and lower distensibility  
300 distinguish a higher mortality risk group, even with similar PaO<sub>2</sub>/FiO<sub>2</sub>. [32] Nevertheless, these  
301 measures require advanced monitoring, which is not frequently available in scarce resource  
302 settings. Numerous studies have explored other biomarkers to enhance prognostication in  
303 patients with ARDS.

304

305 Red bloodline characteristics have raised concern in the physiopathology of COVID-19 and  
306 ARDS. In our study, either high or low Hb values were associated with higher likelihood of death,  
307 giving a nonlinear, U-shaped correlation between hemoglobin concentration and probability of  
308 death in GAM (Fig. 1C). However, the oxygenation index measured by the SpO<sub>2</sub>/FiO<sub>2</sub> ratio  
309 modified this effect. Patients with similar SpO<sub>2</sub>/FiO<sub>2</sub> had different mortality probabilities according  
310 to Hb concentration (Fig. 2).

311

312 Taneri et al. conducted a meta-analysis including 139 observational studies. They reported a  
313 weighted mean difference (WMD) of -4.08 g/L (CI -5.12; -3.05) between moderate and severe  
314 cases in patients with COVID-19. However, among 27 studies, there were no significant  
315 differences in the pooled mean Hb concentrations between survivors and nonsurvivors, with a  
316 WMD of -0.26 g/L (95% CI -2.37; 1.85).[21] In an in silico analysis, Liu et al. proposed a direct  
317 effect of SARS-CoV-2 proteins ORF1ab, ORF10, and ORF3a in the Hb beta chain competing  
318 against iron. This leads to a functional loss of hemoglobin and hemolysis. However, given that  
319 these hypotheses proposed a nondescribed protein–protein hemoglobin degradation pathway,  
320 some authors criticized it for its flawed methods and unreliability.[33,34] In the same way, De  
321 Martino et al. did not find differences in the hemoglobin dissociation curves or hemolytic

322 biomarkers between patients with COVID-19-related ARDS and patients with ARDS from other  
323 causes.[35]

324

325 Histopathological descriptions of the lung tissue of patients with ARDS describe the presence of  
326 RBCs. However, they are considered a marker for the increased permeability of the endothelial-  
327 alveolar barrier. Nevertheless, recently, the role of RBCs and cell-free Hb has been discussed as  
328 a central phenomenon in the progression of acute respiratory infection to sepsis, critical illness,  
329 and ARDS pathogenesis. The proinflammatory state steers lipid peroxidation, pump damage,  
330 changes in calcium influx, and 2,3-DPG concentrations. This leads to RBC membrane changes,  
331 facilitating their aggregation, inducing thrombotic events, and hemolysis with cell-free hemoglobin  
332 and iron unstable (Fe 4+) group liberation. These perpetuate an injury cycle with nitric oxide  
333 consumption, vasoconstriction, inflammation, and increased endothelial permeability.[36]  
334 Oxidative and inflammatory damage, and thrombosis with cell aggregation in capillary beds,  
335 might explain the harmful effect of polycythemia that we observed in our sample.

336

337 Furthermore, other RBC biomarkers are related to ARDS prognosis. Some authors have studied  
338 red blood cell distribution width (RDW) and circulating nucleated red blood cells (NRBCs) as  
339 prognostic markers. A RDW >14.5 was independently associated with mortality at 30 and 90 days  
340 (OR 1.91, CI 95% 1.08–3.39 and 2.56, CI 95% 1.50–4.37, respectively).[37,38] The NRBCs are  
341 biomarkers of increased erythropoietic activity. They are related to hypoxemia and inflammation.  
342 A study reported a significant difference in the proportion of deaths (50.8% versus 27.3% [p  
343 <0.001]) between patients with and without NRBCs. Additionally, patients with severe cases had  
344 a higher number of NRBCs, and they were detectable for a longer time. Additionally, there was a  
345 negative correlation between the NRBC absolute count and survival time.[39]

346

347 Otherwise, we found that a higher NLR was related to worse outcomes. Consistently, previous  
348 studies have proposed this relation as a biomarker of severe disease.[40,41] It is used in  
349 validated evaluation scales such as COVID-GRAM for predicting critical illness risk.[40] Kilercik et

350 al. evaluated the performance of CBC measures for predicting risk of COVID-19 severity and  
351 mortality. They reported that an NLR >5.23 had a sensitivity and specificity for mortality of 85.6%  
352 and 56.8%, respectively. Additionally, with a cutoff point of 4.4, NLR had a sensitivity of 78.5%  
353 and specificity of 68.2% for predicting severe disease.[42]

354

355 A lower ALC is related to the risk of COVID-19 progression. The CALL score uses it as a variable  
356 for predicting pneumonia progression.[43] Patients with COVID-19 who developed ARDS  
357 demonstrated sustained CD4+ and CD8+ lymphopenia compared to patients without COVID-19-  
358 related ARDS .[44] Additionally, the absolute counts of B, T, and natural killer (NK) cells were  
359 found to be significantly lower in patients with severe COVID-19 cases than in patients with  
360 nonsevere COVID-19 cases.[8] Immune activation by long-term antigen exposure throughout life  
361 is related to sterile and chronic low-grade inflammation associated with chronic diseases,  
362 cardiovascular risk, obesity, and cancer.[45] This process leads to a senescent adaptive immune  
363 system with a predominance of an innate response, which could generate an exaggerated  
364 inflammatory response leading to sepsis. The NLR could be a biomarker of this  
365 predominance.[44,45]

366

367 We also found that male patients were more likely to die in the hospital than females. Analysis of  
368 other coronaviruses, such as SARS and MERS, also showed an excess of mortality in male  
369 patients. [46,47] Interestingly, the erythroid response to chronic high-altitude hypoxia might be  
370 influenced by sex hormones. Chronic mountain sickness (CMS) is rare in Andean females of  
371 reproductive age, but its incidence presents a sharp increase with menopause. Additionally, CMS  
372 is more frequent in Andean male patients than in female patients. Estrogens might confer  
373 protection against excessive erythrocytosis in CMS or Monge's disease. At physiologic  
374 concentrations in vitro, estrogens were related to lower RBC counts than testosterone. Estrogens  
375 regulate *EPO*, *HIF1A*, *GATA1*, *VEGF*, genes related to erythropoiesis and erythroid apoptosis  
376 mechanisms.[48] These findings suggest that sex hormones moderate the erythropoietic



377 response of chronic exposure to hypoxia and may contribute to the mortality excess in male  
378 patients with COVID-19.

379

380 This study has some limitations. First, we only considered admission values as predictors of  
381 mortality. Patients with COVID-19 might have different behaviors with several kinds of  
382 intervention requirements that we did not observe, and which could modify the prognosis.  
383 Additionally, we did not consider certain variables related to the Hb dissociation curve as  $PCO_2$  or  
384 acid-base status, which might be associated with residual confusion bias. Furthermore, we did  
385 not consider the pharmacological history that could affect the baseline CBC. Lastly, given the  
386 retrospective nature of our study, and since the data were gathered from clinical records, we  
387 could not guarantee a uniform measurement for each variable. It is necessary to note that no  
388 effect can be associated with high-altitude exposure given the absence of a comparative group.  
389 The variables studied might also be modified in chronic pulmonary disease or tobacco use.  
390 However, including those variables in the purposeful selection of covariates for multivariate  
391 analysis showed us that they lacked significance. This study allowed us to hypothesize that the  
392 adaptative mechanism for chronic hypoxia modifies the pathological process in respiratory  
393 diseases. Further studies are required to understand this biological interaction.

394

## 395 **Conclusion**

396 This study explored the role of the oxygenation index and CBC biomarkers taken at admission as  
397 predictors of in-hospital mortality. We found in GAM that  $SpO_2/FiO_2$ , Hb, and NLR were  
398 independently associated with mortality following nonlinear trends. Both low and high Hb  
399 concentrations showed a higher likelihood of death. Decreases in  $SpO_2/FiO_2$  were associated  
400 with a sharp increase in the likelihood of death. However, we found that the effects of Hb and  
401  $SpO_2/FiO_2$  on mortality were modified by each other. For instance, patients with similar oxygen  
402 index values had different death probabilities based on their Hb at admission. The likelihood of  
403 death of patients with a low  $SpO_2/FiO_2$  increased proportionally as Hb increased. The CART

404 model showed that patients with a  $\text{SpO}_2/\text{FiO}_2 > 324$  and an Hb  $> 12$  g/dl had the lowest mortality  
405 risk (10%). In contrast, normoxic but anemic patients with Hb  $< 12$  g/dl and NLR  $> 4$  had a higher  
406 probability of death (57%). Finally, patients whose  $\text{SpO}_2/\text{FiO}_2$  was lower than 324, who were older  
407 than 62 years, and who had a Hb  $\geq 16$  g/dl had the highest mortality risk (90%).

408

## 409 **Author contributions**

410 AMPR and AMRS led and supervised the execution of the research. They contributed to  
411 evidence interpretation, critical reviewing and commenting on the manuscript.

412 DRRL conceptualized the study, conducted the project, collected the data, interpreted the  
413 evidence, and critically reviewed the manuscript.

414 NMG contributed to data curation, formal analysis, and visualization.

415 AFPA conceptualized the study, worked in data curation, formal analysis, visualization, evidence  
416 interpretation, and manuscript drafting.

## 417 **Acknowledgments**

418 We thank Estefania Rodríguez Alvarino, Isabella Sanclemente Mariño, and Mateo Díaz Quiroz for  
419 supporting the literature review, and Elizabeth Cruz Tapias for her work in image editing.

## 420 **Disclosure**

421 The authors report no conflicts of interest in this work.

422

## 423 **References**

- 424 1. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard  
425 With Vaccination Data [Internet]. [cited 2021 Aug 22]. Available from:  
426 <https://covid19.who.int/>
- 427 2. Colombia: WHO Coronavirus Disease (COVID-19) Dashboard With Vaccination Data |

- 428 WHO Coronavirus (COVID-19) Dashboard With Vaccination Data [Internet]. [cited 2021  
429 Aug 22]. Available from: <https://covid19.who.int/region/amro/country/co>
- 430 3. Instituto Nacional de Salud. Coronavirus Colombia [Internet]. 2020 [cited 2020 Sep 22].  
431 Available from: <https://www.ins.gov.co/Noticias/Paginas/Coronavirus.aspx>
- 432 4. Liu W, Tao ZW, Wang L, Yuan ML, Liu K, Zhou L, et al. Analysis of factors associated with  
433 disease outcomes in hospitalized patients with 2019 novel coronavirus disease. *Chin Med*  
434 *J (Engl)* [Internet]. 2020 May 5 [cited 2021 Apr 13];133(9):1032–8. Available from:  
435 [/pmc/articles/PMC7147279/](https://pubmed.ncbi.nlm.nih.gov/347147279/)
- 436 5. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected  
437 with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497–506.
- 438 6. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors  
439 associated with hospital admission and critical illness among 5279 people with  
440 coronavirus disease 2019 in New York City: Prospective cohort study. *BMJ*. 2020;369.
- 441 7. Garibaldi BT, Fiksel J, Muschelli J, Robinson ML, Rouhizadeh M, Perin J, et al. Patient  
442 Trajectories Among Persons Hospitalized for COVID-19 : A Cohort Study. *Ann Intern Med*.  
443 2021;174(1):33–41.
- 444 8. Tian D-S, Qin C, Zhou L, Hu Z, Zhang S, Yang S, et al. Dysregulation of Immune  
445 Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis*  
446 [Internet]. 2020 [cited 2021 Aug 25];71:762–8. Available from:  
447 <https://academic.oup.com/cid/article/71/15/762/5803306>
- 448 9. Yin Tan L, Vaani Komarasamy T, RMT Balasubramaniam V. Hyperinflammatory Immune  
449 Response and COVID-19: A Double Edged Sword. [cited 2021 Nov 25]; Available from:  
450 [www.frontiersin.org](http://www.frontiersin.org)
- 451 10. Woolcott OO, Bergman RN. Mortality Attributed to COVID-19 in High-Altitude Populations.  
452 *High Alt Med Biol*. 2020;21(4):409–16.
- 453 11. Cano-Pérez E, Torres-Pacheco J, Fragozo-Ramos MC, García-Díaz G, Montalvo-Varela  
454 E, Pozo-Palacios JC. Negative Correlation between Altitude and COVID-19 Pandemic in  
455 Colombia: A Preliminary Report. *Am J Trop Med Hyg* [Internet]. 2020 Oct 26 [cited 2021

- 456 Aug 22];103(6):2347–9. Available from:  
457 <https://www.ajtmh.org/view/journals/tpmd/103/6/article-p2347.xml>
- 458 12. Intimayta-Escalante C, Rojas-Bolivar D, Hanco I. Letter to the Editor: Influence of Altitude  
459 on the Prevalence and Case Fatality Rate of COVID-19 in Peru. *High Alt Med Biol.*  
460 2020;21(4):426–7.
- 461 13. Ortiz-Prado E, Patricio Fernandez Naranjo R, Vasconez E, Simbaña-Rivera K, Correa-  
462 Sancho T, Alex Lister ii, et al. Analysis of Excess Mortality Data at Different Altitudes  
463 During the COVID-19 Outbreak in Ecuador. <https://home.liebertpub.com/ham> [Internet].  
464 2021 Dec 13 [cited 2021 Dec 28];22(4):406–16. Available from:  
465 <https://www.liebertpub.com/doi/abs/10.1089/ham.2021.0070>
- 466 14. Trompetero González AC, Mejía EC, Benavides Pinzón WF, Serrato M, Landinéz MP,  
467 Rojas J. Comportamiento de la concentración de hemoglobina, el hematocrito y la  
468 saturación de oxígeno en una población universitaria en Colombia a diferentes Alturas.  
469 *Nutr Hosp.* 2015;32(5):2309–18.
- 470 15. Julian CG. High Altitude During Pregnancy. *Clin Chest Med* [Internet]. 2011;32(1):21–31.  
471 Available from: <http://dx.doi.org/10.1016/j.ccm.2010.10.008>
- 472 16. Pun M, Guadagni V, Bettauer KM, Drogos LL, Aitken J, Hartmann SE, et al. Effects on  
473 cognitive functioning of acute, subacute and repeated exposures to high altitude. *Front*  
474 *Physiol.* 2018;9(AUG):1–15.
- 475 17. Windsor JS. Heights and haematology: the story of haemoglobin at altitude. *Postgr Med J*  
476 [Internet]. 2007 [cited 2021 Feb 26];83:148–51. Available from: [www.postgradmedj.com](http://www.postgradmedj.com)
- 477 18. West JB. Are Permanent Residents of High Altitude Fully Adapted to Their Hypoxic  
478 Environment? *High Alt Med Biol.* 2017;18(2):135–9.
- 479 19. Acevedo LE, Solarte I. Gasimetría arterial en adultos jóvenes a nivel de Bogotá. *Acta*  
480 *Médica Colomb.* 1984 Jan;9(1).
- 481 20. Johanna TR, Hurtado C, Salazar T, De La Peña M. Valores Normales de Gases Arteriales  
482 en Bogotá. *Umbral Científico* [Internet]. 2007 [cited 2021 Dec 21];(10):94–102. Available  
483 from: <https://www.redalyc.org/articulo.oa?id=30401008>

- 484 21. Taneri PE, Gómez-Ochoa SA, Llanaj E, Raguindin PF, Rojas LZ, Roa-Díaz ZM, et al.  
485 Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis. *Eur J*  
486 *Epidemiol* [Internet]. 2020;35(8):763–73. Available from: [https://doi.org/10.1007/s10654-](https://doi.org/10.1007/s10654-020-00678-5)  
487 020-00678-5
- 488 22. Hayden SJ, Albert TJ, Watkins TR, Swenson ER. Anemia in Critical Illness: Insights into  
489 Etiology, Consequences, and Management. *Am J Respir Crit Care Med* [Internet]. 2012  
490 May 15 [cited 2021 Dec 28];185(10):1049. Available from: [/pmc/articles/PMC5448578/](https://pubmed.ncbi.nlm.nih.gov/31111111/)
- 491 23. Fuentes S, Chowdhury YS. Fraction of Inspired Oxygen. *StatPearls* [Internet]. 2021 Jan  
492 17 [cited 2021 Aug 24]; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK560867/>
- 493 24. Hosmer DW, Lemeshow S, Sturdivant RX. *Applied Logistic Regression*. Vol. 47,  
494 *Biometrics*. 1991. 1632 p.
- 495 25. Wood SN. *Generalized additive models*. 2° Ed. Blitzstein JK, Faraway JJ, Tanner M, Zidek  
496 J, editors. Vol. 1, *Statistical Science*. CRC Press; 1986. 297–310 p.
- 497 26. Leo B, Jerome F, Richard A O, Charles J S. *Classification and Regression Trees*. Vol. 1.  
498 Florida: Chapman & Hall; 1984. 1–384 p.
- 499 27. COVID-19 Hospital Data - In-hospital mortality among confirmed COVID-19 encounters by  
500 week [Internet]. [cited 2021 Aug 24]. Available from:  
501 <https://www.cdc.gov/nchs/covid19/nhcs/hospital-mortality-by-week.htm>
- 502 28. Rice TW, Wheeler AP, Bernard GR, Hayden DL, Schoenfeld DA, Ware LB. Comparison of  
503 the SpO<sub>2</sub>/FIO<sub>2</sub> ratio and the PaO<sub>2</sub>/FIO<sub>2</sub> ratio in patients with acute lung injury or ARDS.  
504 *Chest*. 2007;132(2):410–7.
- 505 29. Pratik P. Pandharipande, Shintani AK, Hagerman HE, Jacques PJS, Rice TW, Sanders  
506 NW, et al. Derivation and validation of SpO<sub>2</sub>/FiO<sub>2</sub> ratio to impute for PaO<sub>2</sub>/FiO<sub>2</sub> ratio in  
507 the respiratory component of the Sequential Organ Failure Assessment (SOFA) Score.  
508 *Crit Care Med* [Internet]. 2009;23(1):1–7. Available from:  
509 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624763/pdf/nihms412728.pdf>
- 510 30. Lu X, Jiang L, Chen T, Wang Y, Zhang B, Hong Y, et al. Continuously available ratio of  
511 SpO<sub>2</sub>/FIO<sub>2</sub> serves as a noninvasive prognostic marker for intensive care patients with

- 512 COVID-19. *Respir Res.* 2020;21(1):1–4.
- 513 31. Riviello ED, Kiviri W, Twagirumugabe T, Mueller A, Banner-Goodspeed VM, Officer L, et  
514 al. Hospital incidence and outcomes of the acute respiratory distress syndrome using the  
515 Kigali modification of the Berlin definition. *Am J Respir Crit Care Med.* 2016;193(1):52–9.
- 516 32. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute  
517 respiratory distress syndrome: The Berlin definition. *JAMA - J Am Med Assoc.*  
518 2012;307(23):2526–33.
- 519 33. Wenzhong L, Hualan L. COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures  
520 the Porphyrin to Inhibit Human Heme Metabolism. *ChemRxiv.* 2020;105.
- 521 34. R R. Flawed methods in “COVID-19: Attacks the 1-Beta Chain of Hemoglobin and  
522 Captures the Porphyrin to Inhibit Human Heme Metabolism.” 2020 Apr 14 [cited 2021 Jun  
523 19]; Available from: <https://europepmc.org/article/PPR/PPR151013>
- 524 35. DeMartino AW, Rose JJ, Amdahl MB, Dent MR, Shah FA, Bain W, et al. No evidence of  
525 hemoglobin damage by SARS-CoV-2 infection. *Haematologica.* 2020;105(12):2769–73.
- 526 36. Janz DR, Ware LB. The role of red blood cells and cell-free hemoglobin in the  
527 pathogenesis of ARDS [Internet]. Vol. 3, *Journal of Intensive Care.* BioMed Central Ltd.;  
528 2015 [cited 2021 Feb 26]. p. 20. Available from:  
529 <http://www.jintensivecare.com/content/3/1/20>
- 530 37. Yu XS, Chen ZQ, Hu YF, Chen JX, Xu WW, Shu J, et al. Red blood cell distribution width  
531 is associated with mortality risk in patients with acute respiratory distress syndrome based  
532 on the Berlin definition: A propensity score matched cohort study. *Hear Lung* [Internet].  
533 2020 Sep 1 [cited 2021 Mar 19];49(5):641–5. Available from:  
534 <https://pubmed.ncbi.nlm.nih.gov/32434701/>
- 535 38. Wang B, Gong Y, Ying B, Cheng B. Relation between Red Cell Distribution Width and  
536 Mortality in Critically Ill Patients with Acute Respiratory Distress Syndrome. *Biomed Res*  
537 *Int* [Internet]. 2019 [cited 2021 Mar 19];2019. Available from:  
538 <https://pubmed.ncbi.nlm.nih.gov/31016186/>
- 539 39. Menk M, Giebelhäuser L, Vorderwülbecke G, Gassner M, Graw JA, Weiss B, et al.

- 540 Nucleated red blood cells as predictors of mortality in patients with acute respiratory  
541 distress syndrome (ARDS): an observational study. *Ann Intensive Care* [Internet]. 2018  
542 Dec 1 [cited 2021 Mar 19];8(1):42. Available from: [/pmc/articles/PMC5869325/](https://pubmed.ncbi.nlm.nih.gov/35869325/)
- 543 40. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and validation of a  
544 clinical risk score to predict the occurrence of critical illness in hospitalized patients with  
545 COVID-19. *JAMA Intern Med*. 2020;180(8):1081–9.
- 546 41. Kuri-Cervantes L, Betina Pampena M, Meng W, Rosenfeld AM, G Ittner CA, Weisman AR,  
547 et al. Comprehensive mapping of immune perturbations associated with severe COVID-  
548 19. *Sci Immunol* [Internet]. 2020 [cited 2021 Aug 25];5. Available from:  
549 <http://immunology.sciencemag.org/>
- 550 42. Kilercik M, Demirelce Ö, Serdar MA, Mikailova P, Serteser M. A new haematocytometric  
551 index: Predicting severity and mortality risk value in COVID-19 patients. *PLoS One*.  
552 2021;16(8 August):1–19.
- 553 43. Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P, et al. Prediction for Progression Risk in  
554 Patients With COVID-19 Pneumonia: The CALL Score. *Clin Infect Dis* [Internet]. 2020 Sep  
555 12 [cited 2021 Apr 13];71(6):1393–9. Available from:  
556 <https://academic.oup.com/cid/article/71/6/1393/5818317>
- 557 44. Hue S, Beldi-Ferchiou A, In' I, Bendib I, Surenaud M, Fourati S, et al. Uncontrolled Innate  
558 and Impaired Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory  
559 Distress Syndrome. *Am J Respir Crit Care Med* [Internet]. 2017 [cited 2021 Aug  
560 25];202:1509–19. Available from: [www.atsjournals.org](http://www.atsjournals.org).
- 561 45. Fulop T, Larbi A, Dupuis G, Page A Le, Frost EH, Cohen AA, et al. Immunosenescence  
562 and inflamm-aging as two sides of the same coin: Friends or Foes? [Internet]. Vol. 8,  
563 *Frontiers in Immunology*. Frontiers Media S.A.; 2018 [cited 2021 Jun 15]. Available from:  
564 <https://pubmed.ncbi.nlm.nih.gov/29375577/>
- 565 46. Karlberg J, Chong DSY, Lai WYY. Do Men Have a Higher Case Fatality Rate of Severe  
566 Acute Respiratory Syndrome than Women Do? *Am J Epidemiol* [Internet]. 2004 Feb 1  
567 [cited 2021 Jun 15];159(3):229–31. Available from:

568 <https://pubmed.ncbi.nlm.nih.gov/14742282/>

569 47. Alghamdi IG, Hussain II, Almalki SS, Alghamdi MS, Alghamdi MM, El-Sheemy MA. The  
570 pattern of Middle east respiratory syndrome coronavirus in Saudi Arabia: A descriptive  
571 epidemiological analysis of data from the Saudi Ministry of Health. *Int J Gen Med*  
572 [Internet]. 2014 Aug 20 [cited 2021 Jun 15];7:417–23. Available from:

573 <https://pubmed.ncbi.nlm.nih.gov/25187734/>

574 48. Azad P, Villafuerte FC, Bermudez D, Patel G, Haddad GG. Protective role of estrogen  
575 against excessive erythrocytosis in Monge’s disease. *Exp Mol Med* [Internet]. 2021 [cited  
576 2021 Nov 24];53:125–35. Available from: <https://doi.org/10.1038/s12276-020-00550-2>

577

578 **Notes:**

579 **Abbreviations:** AIC: Akaike information criteria; ALC: Absolute lymphocyte count; ANC: Absolute  
580 neutrophil count; ARDS: Acute respiratory distress syndrome; BMI: Body mass index; CART:  
581 Classification and regression tree; CBC: Complete blood count; CKD: Chronic kidney disease;  
582 CMS: Chronic mountain sickness; COPD: Chronic obstructive pulmonary disease; EPO:  
583 Erythropoietin; FiO<sub>2</sub>: Fraction inspired O<sub>2</sub>; GAM: Generalized additive model; Hb: Hemoglobin  
584 concentration (g/dL); HIF-1 $\alpha$ : Hypoxia-inducible factor 1- $\alpha$ ; HIV: Human immunodeficiency virus;  
585 HUM: Hospital Universitario Mayor; MAP: Mean arterial pressure; MASL: Meters above sea level;  
586 NK: Natural killer cells; NLR: Neutrophil to lymphocyte ratio; NRBCs: Nucleated red blood cells  
587 circulating; PCO<sub>2</sub>: Partial CO<sub>2</sub> pressure; RBC: Red blood cells count; RDW: Red blood cell  
588 distribution width; SpO<sub>2</sub>: Peripheral O<sub>2</sub> saturation; VEGF: Vascular-endothelial growth factor;  
589 WBC: White blood cell count; WMD: Weighted mean difference.

590

591




592

593

594

595



**1A****1B****1C****Figure 1**




Figure 2




Figure 3